Financials data is unavailable for this security.
View more
Year on year BioMarin Pharmaceutical Inc grew revenues 15.42% from 2.10bn to 2.42bn while net income improved 18.43% from 141.56m to 167.65m.
Gross margin | 78.95% |
---|---|
Net profit margin | 11.71% |
Operating margin | 11.81% |
Return on assets | 4.74% |
---|---|
Return on equity | 6.25% |
Return on investment | 5.49% |
More ▼
Cash flow in USDView more
In 2023, BioMarin Pharmaceutical Inc did not generate a significant amount of cash. However, the company earned 159.26m from its operations for a Cash Flow Margin of 6.58%. In addition the company used 111.24m on investing activities and also paid 18.73m in financing cash flows.
Cash flow per share | 2.15 |
---|---|
Price/Cash flow per share | 30.29 |
Book value per share | 28.41 |
---|---|
Tangible book value per share | 26.01 |
More ▼
Balance sheet in USDView more
Current ratio | 4.27 |
---|---|
Quick ratio | 2.62 |
Total debt/total equity | 0.1098 |
---|---|
Total debt/total capital | 0.099 |
More ▼